August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Milos Grujic: Patient-Reported Outcomes with Talazoparib plus Enzalutamide
Apr 19, 2025, 01:19

Milos Grujic: Patient-Reported Outcomes with Talazoparib plus Enzalutamide

Milos Grujic, Head of Department of the subspecialist cabinets at the Center for Radiation Oncology at the University Clinical Center Kragujevac, shared a post on X:

“In TALAPRO-2, Talazoparib plus Enzalutamide significantly delayed QoL deterioration in mCRPC patients with HRR alterations.
Median: 27.1 vs 19.3 months
HR: 0.69 | p=0.032
Better QoL, longer control.
Lancet Oncology 2025.”

Milos Grujic: Patient-Reported Outcomes with Talazoparib plus Enzalutamide